- Motley Fool•21 hours ago
Valeant Pharmaceuticals' efforts to dispose of non-core assets to reduce its debt may be thwarted by unrealistic sale price expectations.
- Insider Monkey•yesterday
Although several major companies have recently reported earnings, shares of five other companies, Clayton Williams Energy, Inc. (NYSE:CWEI), Netflix, Inc. (NASDAQ:NFLX), Tesla Motors Inc (NASDAQ:TSLA), Valeant Pharmaceuticals Intl Inc (NYSE:VRX), and SAExploration Holdings, Inc. (NASDAQ:SAEX), are trending for various reasons. In this article, let’s examine the reasons each stock is in the spotlight and see how […]
- Barrons.com•2 days ago
Earlier today, we noted that JPMorgan had warned clients to avoid Valeant Pharmaceuticals International (VRX) ahead of its earnings. In an appearance on CNBC, however, Legg Mason fund manager Bill Miller argued that Valeant's shares could double in three years. From Bloomberg: Bill Miller, who is best known for beating the S&P 500 Index for 15 straight years, says he has been buying Valeant Pharmaceuticals International Inc. and financial stocks such as OneMain Holdings Inc (OMF).
Valeant Pharmaceuticals International, Inc. (VRX.TO)
Toronto - Toronto Delayed Price. Currency in CAD
|Day's Range||29.03 - 29.61|
|52wk Range||24.32 - 167.30|
|1y Target Est||N/A|
|P/E Ratio (ttm)||-9.90|
|Avg Vol (3m)||1,050,347|
|Dividend & Yield||0.00 (0.00%)|